RxDoctor Payments Data

Erin McFadden, MD

Internal Medicine · Scranton, PANPI 1932369626

Payments from drug & device makers

$1,725in general payments, 2019–2025

Across 68 payments — averaging $25.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$325
  • Braeburn Inc.$217
  • AstraZeneca$214
  • Amgen$211
  • Medtronic$170
  • GSK$118
  • plus $471 from 13 others

What the payments were for

  • Food & beverage$1,71099%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,725 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,544
Medicare patients
55
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$51,663
JardianceEmpagliflozin42$34,707
JanuviaSitagliptin Phosphate35$26,279
TrulicityDulaglutide25$23,989
XareltoRivaroxaban29$21,423
OzempicSemaglutide16$19,718
MounjaroTirzepatide18$18,382
AbrysvoRsv Vacc, Pref A And Pref B/Pf44$13,920
ShingrixVaricella-Zoster Ge/As01b/Pf58$12,889
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$12,073
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt15$8,930
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$7,567
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,736
Boostrix TdapDiphth,pertuss(Acell),tet Vac57$3,971
PremarinEstrogens, Conjugated12$3,833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo, Premarin$47$69,415124 claims
Boehringer IngelheimJardiance$15$34,70742 claims
Novo NordiskOzempic$81$19,71816 claims
GSKShingrix, Anoro Ellipta$118$18,62570 claims
AbbVieCreon$325$1,44514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Scranton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →